These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 20085866)

  • 1. Plasma nucleosome levels might predict response to therapy in patients with advanced non-small-cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Clin Lung Cancer; 2010 Jan; 11(1):36-44. PubMed ID: 20085866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleosomes, ProGRP, NSE, CYFRA 21-1, and CEA in monitoring first-line chemotherapy of small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Clin Cancer Res; 2008 Dec; 14(23):7813-21. PubMed ID: 19047109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of utility of plasma TNF-alpha level in predicting therapeutic efficacy in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Singh V; Mohan A; Bharti AC; Das BC
    Cytokine; 2010 Sep; 51(3):245-8. PubMed ID: 20599393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    Eur Respir J; 2010 Oct; 36(4):885-92. PubMed ID: 20185420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer.
    Holdenrieder S; Stieber P; von Pawel J; Raith H; Nagel D; Feldmann K; Seidel D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):5981-7. PubMed ID: 15447981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleosomes and CYFRA 21-1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer.
    Holdenrieder S; von Pawel J; Dankelmann E; Duell T; Faderl B; Markus A; Siakavara M; Wagner H; Feldmann K; Hoffmann H; Raith H; Nagel D; Stieber P
    Lung Cancer; 2009 Jan; 63(1):128-35. PubMed ID: 18571761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of plasma TGF-β1 level in predicting therapeutic efficacy and prognosis in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Mohan A; Singh V; Bharti AC; Das BC
    Cancer Invest; 2011 Mar; 29(3):202-7. PubMed ID: 21280981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of plasma vascular endothelial growth factor in monitoring first-line chemotherapy in patients with advanced non-small cell lung cancer.
    Kumar S; Guleria R; Singh V; Bharti AC; Mohan A; Das BC
    BMC Cancer; 2009 Dec; 9():421. PubMed ID: 19958548
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-reactive protein as a monitor of chemotherapy response in advanced non-small cell lung cancer (CML study).
    Srimuninnimit V; Ariyapanya S; Nimmannit A; Wonglaksanapimon S; Akewanlop C; Soparattanapaisarn N
    J Med Assoc Thai; 2012 Feb; 95 Suppl 2():S199-207. PubMed ID: 22574550
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy.
    Sörenson S; Fohlin H; Lindgren A; Lindskog M; Bergman B; Sederholm C; Ek L; Lamberg K; Clinchy B
    Eur J Cancer; 2013 Jan; 49(1):115-20. PubMed ID: 22951014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum carcinoembryonic antigen level as a surrogate marker for the evaluation of tumor response to chemotherapy in nonsmall cell lung cancer.
    Ishiguro F; Fukui T; Mori S; Katayama T; Sakakura N; Hatooka S; Mitsudomi T
    Ann Thorac Cardiovasc Surg; 2010 Aug; 16(4):242-7. PubMed ID: 21057440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
    Buccheri G; Ferrigno D
    J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
    Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
    Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of tumor markers in evaluating chemotherapy response and prognosis in Chinese patients with advanced non-small cell lung cancer.
    Jin B; Huang AM; Zhong RB; Han BH
    Chemotherapy; 2010; 56(6):417-23. PubMed ID: 21079400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxidative stress in non-small cell lung cancer patients after chemotherapy: association with treatment response.
    Gupta A; Srivastava S; Prasad R; Natu SM; Mittal B; Negi MP; Srivastava AN
    Respirology; 2010 Feb; 15(2):349-56. PubMed ID: 20199646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
    Ebert W; Muley T
    Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
    Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
    Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early and specific prediction of the therapeutic efficacy in non-small cell lung cancer patients by nucleosomal DNA and cytokeratin-19 fragments.
    Holdenrieder S; Stieber P; VON Pawel J; Raith H; Nagel D; Feldmann K; Seidel D
    Ann N Y Acad Sci; 2006 Sep; 1075():244-57. PubMed ID: 17108218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Baseline levels and decrease in serum soluble intercellular adhesion molecule-1 during chemotherapy predict objective response and survival in patients who have advanced non-small-cell lung cancer.
    Qian Q; Zhan P; Yu L; Shi Y; Cheng J; Wei S; Wang Q; Song Y
    Clin Lung Cancer; 2011 Mar; 12(2):131-7. PubMed ID: 21550560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of oral topotecan in advanced non-small cell lung cancer.
    White SC; Cheeseman S; Thatcher N; Anderson H; Carrington B; Hearn S; Ross G; Ranson M
    Clin Cancer Res; 2000 Mar; 6(3):868-73. PubMed ID: 10741709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.